Endoscopy 2020; 52(S 01): S307
DOI: 10.1055/s-0040-1704984
ESGE Days 2020 ePoster presentations
Thursday, April 23, 2020 09:00 – 17:00 Endoscopic ultrasound ePoster area
© Georg Thieme Verlag KG Stuttgart · New York

ENDOSCOPIC ULTRASOUND-GUIDED RADIOFREQUENCY ABLATION OF PANCREATIC METASTASIS FROM RENAL CELL CANCER: FEASIBILITY AND SAFETY

D Biasutto
1   Campus Bio-Medico, Rome, Italy
,
S Stigliano
1   Campus Bio-Medico, Rome, Italy
2   Sapienza University of Rome, Rome, Italy
,
F Covotta
1   Campus Bio-Medico, Rome, Italy
,
FMD Matteo
1   Campus Bio-Medico, Rome, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
23 April 2020 (online)

Also available at
 

Aims Renal cell carcinoma (RCC) is the most common renal cancer in adults. Up to 50% of patients will develop metastases after nephrectomy with a 5-year survival rate of 10%-15%. Pancreas is an elective site for RCC metastases. Surgery is the first choice treatment for pancreatic metastases. For not-resectable pancreatic metastases therapeutical options are limited. Radiofrequency ablation (RFA) has been successfully performed for the treatment of several not-resectable solid tumours. Previous studies have demonstrated the feasibility and safety of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for the treatment of pancreatic lesions. However, there are no data regarding its use in the treatment of pancreatic metastases from RCC.

To evaluate feasibility and safety of EUS-RFA in the treatment of pancreatic metastases from RCC.

Methods Single centre prospective study on patients with non-resectable RCC pancreatic metastases or not amenable to surgery. All patients underwent EUS-RFA with a monopolar, 19 G RFA needle (Endoscopic UltraSound guided Radiofrequency Ablation electrode; EUSRA) with a RF power of 30 W.

All patients underwent CT/MRI scan after 24 hours from the procedure. Feasibility was defined as the possibility of inserting the needle in the lesion and applying the radiofrequency. Safety was defined by collecting data of any complication occurred within 3 months of follow-up.

Results From January to August 2019, three patients were enrolled (2 women; mean age 64 ± 19 years). Overall, four lesions were treated (Mean size 26 ± 17 mm). 3 out of 4 lesions were located in pancreatic head.

The procedure resulted feasible in 100% of cases. No complications occurred after the treatment.

The post-procedural imaging showed in all cases the presence of a necrotic area in the site of treatment.

Conclusions EUS-RFA seems to be a feasible and safe technique for the treatment of not resectable pancreatic metastases from RCC. Further studies are necessary to determine the efficacy of this treatment.